text:
By Hara Estroff Marano, published on February 1, 2004 - last reviewed on June 9, 2016
Whether we admit it or not, power is an essential ingredient of
life. It is present in every single human action and transaction; it is
our ability to produce an effect, to make what we want happen. Usually,
its presence is unspoken. Part of the problem is that when we think of
power, most of us think of dominance—command and control. But
that's only one type of power.
Whatever else it is, that's definitely not authentic power.
According to Ethel S. Person, a well-known psychiatrist and author of
Feeling Strong: How Power Issues Affect Our Ability to Direct
Our Own Lives, authentic power arises strictly from within, an
expression of personal will. It is contingent on our ability to trust our
own instincts and hunches.
Many of us walk around feeling powerless. We procrastinate and fail
to apply ourselves to the work before us. We fail to control our weight.
We fear rejection and fail to start a conversation with a newcomer. We
shrink from confronting others. As Person explains, we can't even
reach our full humanity without some exercise of power, the need for
which is wired in, a basic part of our motivational system. We have a
need for power.
How do we experience ourselves as authentically powerful? Authentic
power is about self-governance, says Person. It "encompasses the
ability to face adversity, to overcome fear and inhibition, to be
sufficiently in touch with our inner lives that we are genuinely able to
express ourselves and chart our life's direction, to be open to a
range of interpersonal relationships, to be assertive without being
confrontational, and to create meaning in our lives."
We aren't born with it. And we don't get there without
struggle. And once we have it we don't keep it forever; we have to
continue to struggle to maintain it. The possession of authentic power,
then, is an ongoing process.
"We often assume that worldly power confers inner
strength," says Person. Yet the feeling of authentic power, of
inner strength, is not necessarily, and perhaps only rarely, associated
with power in the external world. To establish a
raison d'etre, whether in work or love or
religious devotion, to commit to activities that one chooses, to be able
to live in the moment without abandoning either the past or the future,
to have a life relatively free of fear, anger or envy and filled with
love and concern for at least a few others—these are all facets of
authentic power. Authentic power is the ability to live fully, with few
regrets and fewer recriminations. When we are internally free to pursue
our goals, we experience neither excessive apathy nor doubt, and we
remain untroubled by fear of failure or of success.
"Authentic power is not the same thing as worldly power. Like
the proverbial needle in the haystack, it is often difficult to find
those among us who feel authentically powerful, who feel anything like
inner strength or a sense of being in command of themselves.
It's perhaps even harder to identify people who experience
themselves as genuinely powerful among those apparently powerful people
who inhabit the headlines.
"Most of us are neither totally powerless nor totally
powerful but have some combination of weakness and strengths. Dominance
is not the same thing as authentic power; in fact those who rely on
dominating others to establish their own self-esteem are often papering
over an underlying sense of weakness and often doubt whether they are
authentically loved or even liked. Nor should we view vulnerability as
synonymous with weakness. To develop real empathy, we must at one time or
another have permitted ourselves to feel frightened, overwhelmed or
helpless. Indeed, a certain amount of strength is required for us to open
ourselves up and express vulnerability," says Person.
"Authentic power wells up from within, and it seldom appears
full-blown early in life. Rather, it is an outcome of our ability to
integrate our experiences in such a way that even adversity is ultimately
incorporated into the process of growth. Authentic power is gained
through vigorous participation in life, coupled with an openness to new
experiences, emotional sure-footedness, strong ties to other people, the
ability to find interest and pleasure in whatever we encounter and, most
of all, the ability to construct meaning in our lives."


text:
Programming a computer is a tedious business, but it's fun, too. One of the fun aspects of programming is learning about new ways to use an old tool. Recently, I was contracted to fix a dozen bugs in a large, complex, Linux®, Apache, MySQL, and Linux, Apache, MySQL, PHP/Perl (LAMP)-based content-management system (CMS). The architecture of the CMS was the standard LAMP model, with Enterprise Red Hat Linux running Apache V2.0. The code that drove the Web sites consisted of a few hundred PHP source modules spread out over 30 subdirectories in the Apache document root directory. The Apache and MySQL portions of the system required no changes, so all my bug-busting activities were to occur in the PHP workspace.
After spending considerable time learning how the CMS worked, I grew to appreciate the
system's elegant design and I realized that, as in most mature programming
environments, this system relied on only a small number of the available PHP functions.
(Shades of the old 80/20 rule here, where 80 percent of the work is accomplished with
20 percent of the available functions.) This article shows how the process of debugging
an unknown but complex system can help you learn about those little-used functions and
provides examples of how to apply your new knowledge by using the rich functionality of
syslog() function.
Under the microscope
With literally hundreds of functions available in the PHP programming language, some (dare I say most?) functions are never used unless you read about them in articles like this one. Another way to learn more about the language is to debug programs that others have written in it. I'm always impressed by the creative ways in which programmers use the tools.
Debugging, like computer programming, is part science and part art. When tracking down obscure bugs in a system that you didn't create, you need to have a good feel for where they manifest themselves in the code. With hundreds of code modules to deal with, a good place to begin is where the output revealing the bug is found, then work your way backward from there to isolate the problem.
Say, for example, that a calculated value that was being output is known to be incorrect. You must devise some way to see the intermediary values that lead up to the problem. Another problem may manifest itself with bad data coming from an important database query. You need to be able to see the SQL statement generated (and submitted by the code to the MySQL engine) to see whether that's where the problem lies.
One age-old technique for doing this is to insert code that simply prints these strings and values. Unfortunately, with a tool like PHP, or any Web-based application, you don't want to clutter up the natural output of systems like this (that is, HTML code being sent to the browser) with debugging information, especially if the system you're examining is a production server.
You could create a custom logging file and write log messages to it, but why not use the tools that have already been provided for you? Always remember: Don't bury your tools. The time spent seeing whether the language authors have already provided a library routine or function to do something you suspect would be a commonly needed function is well spent. In fact, anytime you suspect that something should obviously be part of a programming package, it probably is.
I realized that what I needed to use was something similar to the syslog functionality
of UNIX®. I thought it likely that PHP would have a hook into the syslog
functionality, so upon a quick review of the PHP documentation, I found it! The PHP
syslog() function is one that I had overlooked for many
years until I was contracted to do this project. With
syslog(), I was able to hunt down and exterminate most of the bugs
in the production system without introducing side effects other than the minute amount
of time it took for each function to execute.
As you grow in your knowledge and become more skilled in your craft, different ways of doing things become apparent, and some way will eventually become the obvious way to perform the required task. What you must always keep in mind is that what is obvious to you is not obvious to other people. What may be simple to you can present a mountain of complexity to others.
Using a tool like the
syslog() function keeps complexity
under control and provides the added benefit of allowing easy customizations through
configuration files, such as syslog.conf. For example, you can insert code to format a
SQL statement, log it to
syslog(), and pass it to MySQL for
execution. Later, a slight modification of the syslog.conf file sends the text to
a different log file or perhaps just to the bit bucket. Weeks or months later, if it
becomes necessary to see what's happening again, another simple change to the
syslog.conf file will restore the functionality.
syslog has a rich and colorful history in the UNIX world. Originally developed as part of the Sendmail project, syslog had proven to be so useful that many other tools have incorporated in its functionality, proving that the simplest ideas are sometimes the most powerful.
In a nutshell, syslog allows applications to write tagged messages to a common set of system log files that can reside where it's convenient for the programmers and network administrators to access. This means, for example, you can configure syslog on a Web server to log system messages on a different server — one that is perhaps a few layers deeper behind the security firewalls and easier for the aforementioned administrators to access. But for my purposes, I just accept the default behavior of files being written to the /var/log directory.
The syslog mechanism is started at boot-up, and its initial behavior is defined by the rules in the syslog.conf file. These rules enable you to finely tune what can and cannot be logged with the mechanism — which, on a high-volume, hard-working server can translate to log files of a manageable size.
Each rule consists of two fields: selector and action. Basically, the selector field selects what facility will be logged (for example, kern, user, mail, lpr) and what priority the facility has. The priority field contains a keyword, such as debug, info, notice, or warning. And the action field of a rule defines what to do with messages of a kind that match the selector field. The rules can specify which file to log the message to, what machine to send the logging message to, what user to send the message to (in the form of console messages), etc.
Study the info and man pages associated with the syslog facility to learn how to configure the system for your needs. In my case, I needed to know what the value of various PHP variables were at different times while the production CMS system was running. I also needed to know when certain modules were started and ended, as well as what various intermediate variable values were. Before getting into specifics about what to log, let's set up the basics for logging.
With your favorite editor, create the file shown in Listing 1, name it test.php and put it where your Apache document root is found (on my system, it's /var/www).
Listing 1. test.php
  <title>PHP Test Page</title>   <?php syslog(LOG_NOTICE, "{$_SERVER['REMOTE_ADDR']}: test.php - PHP Index page accessed."); echo '
PHP Test Page
'; ?>
You should have PHP installed and configured, as well. If not, check Resources for links on how to do this. If you configured everything properly, you should see the following text in your browser when you access the page with the URL http://localhost/test.php:
PHP Test Page
Next, open an X terminal window and type the following command to see what was logged to the /var/log/messages file:
tail /var/log/messages
If all goes well, you should see a line like this one near the end of the listing:
Jul 23 14:43:42 localhost apache2: 127.0.0.1: test.php - PHP Index page accessed.
If you did, that's great. You have now verified that all you need to do to begin detailed debugging of the complex system you're working on.
I have found it a good practice to use
syslog() for all the
PHP/MySQL calls so that every time you interact with the Web site, you can see which
SQL queries are generated in real time to build the page returned to you. A
handy way to make this work is to open a spare X terminal window and use the
tail command with the
-f option for
"live" viewing of the messages log:
tail -f /var/log/messages
What to log
Now that you've verified that the logging works and that you can see the results of the logging mechanism, here are a few tips for shortening the process of learning a foreign system as quickly as possible using these tools.
It's important to know what modules do what beyond what their documentation
may say. For this reason, I like to include logging messages that mark the beginning
and end of the modules. In this way, you can play with the pages of the Web site,
keeping an eye on the spare X terminal window running the
tail -f
/var/log/messages command. In this way, you see which modules execute and in what
order every time the browser requests a new page.
I also like to log the boundaries between different programs being called into action during the running of the PHP code. Examples include when the MySQL calls are made to query the databases or when external programs are called to make formatting changes to data (Extensible Stylesheet Language Transformation (XSLT) engines, for example). The very practice of systematically inserting these checkpoints into each PHP code module helps you get used to the names and locations of the modules. When the code sends you messages you see in the spare X terminal while browsing various pages, you get important feedback that facilitates and enhances your knowledge of the system.
The syslog facility is a powerful tool for debugging an application someone else wrote. It allows you to watch which modules are being executed, which SQL statements are executing, and which variable values change as you navigate the Web site. This helps pinpoint the modules in which you're likely to find problems.
Learn more about the
- Discover the history of syslog on Wikipedia.
- PHP.net is the central resource for PHP developers.
- Check out the "Recommended PHP reading list."
- Browse all the PHP content on developerWorks.
- Expand your PHP skills by checking out IBM developerWorks' PHP project resources.
- To listen to interesting interviews and discussions for software developers, check out developerWorks podcasts.
- Using a database with PHP? Check out the Zend Core for IBM, a seamless, out-of-the-box, easy-to-install PHP development and production environment that supports IBM DB2 V9.
- Stay current with developerWorks' Technical events and webcasts.
- Check out upcoming conferences, trade shows, webcasts, and other Events around the world that are of interest to IBM open source developers.
- Visit the developerWorks Open source zone for extensive how-to information, tools, and project updates to help you develop with open source technologies and use them with IBM's products.
- Watch and learn about IBM and open source technologies and product functions with the no-cost developerWorks On demand demos.
Get products and technologies
- Innovate your next open source development project with IBM trial software, available for download or on DVD.
- Download IBM product evaluation versions, and get your hands on application development tools and middleware products from DB2®, Lotus®, Rational®, Tivoli®, and WebSphere®.
- Participate in developerWorks blogs and get involved in the developerWorks community.
- Participate in the developerWorks PHP Forum: Developing PHP applications with IBM Information Management products (DB2, IDS).
Dig deeper into Open source on developerWorks
developerWorks Premium
Exclusive tools to build your next great app. Learn more.
dW Answers
Ask a technical question
Explore more technical topics
Tutorials & training to grow your development skills

subset: commoncrawl


text:
STMICHEL Genealogy in All Regions
Search criteria: All Regions, Surname STMICHEL
What can you do here?
Search online databases for your ancestors:*
Find related genealogy web sites:
Web sites 1 through 1 of 1
Search for STMICHEL at partner sites:
STMICHEL queries on CousinConnect.com
STMICHEL genealogy records at DistantCousin.
Search Cemetery Records on Interment.net
Share your research with others:
Narrow your search:


text:
Happy Feet – Fashion Is Being Warm at 40 Below 0 – Jim Phillips interviewCurrent Events, Preparedness, Technology November 8, 2010, 14 Comments
Happy Feet – Fashing Is Being Warm at 40 Below 0 – Jim Phillips interview
It wouldn't take much for 1 storm to knock out your power and your heat causing you to freeze to death. Jim Phillips has " Readyness, " down to a science and every Monday J P joins " R J, " on the radio at RBN.
Robert Hender " R J "
Mon Nov 8, 2010
Subject: Extreme Weather Survival
Every Monday Jim Phillips joins " R J, " on the radio at www.republicbroadcasting.org J P travels the country teaching people how to Thrive in " Extreme Weather Conditions. "
Have you heard of PALS? Phillips Arctic Living System is a technology that can be applied to clothing that helps people stay warm at the Arctic Circle. J P suggests you should never use Water Proofing. A raincoat may have good use in the rain, but it could kill you if you try to use it to stay dry, under Arctic Conditions.
Related Articles:
Jim Phillips
Jim Phillips
Jim Phillips
Emergency Preparation – 3 Principles of Our Readyness – Jim Phillips
Survival Guide – Wilderness Survival – Survival School
Top 3 Steps to Survive Economic Collapse – Jim Phillips interview


text:
Users' favorite 4G phones
- Search in name:
- Sort by:
- Date
- Popularity
- Review rating
- User rating
Samsung Galaxy Note 7Compare8.7 reviewAfter two worldwide recalls, the Samsung Galaxy Note 7 was discontinued on October 10 due to multiple reports of units catching fire and/or exploding. In the interest of safety, users who still have a Note 7 in their possession must return the unit to Samsung. Prior to its discontinuation, the Note 7 was one of the best and most powerful Android phones, combining cutting-edge hardware with a number of unique features. These included a refined S Pen stylus, an iris scanner built in for user recognition, as well as water resistance and the highly acclaimed 12MP camera of the Galaxy S7.+ View Specs
8.7Samsung Galaxy Note 7
BlackBerry PrivCompare7.2 reviewThe Priv is BlackBerry's first Android-based smartphone, and is presented as a secure handset. It comes with a new BlackBerry app called DTEK, which reportedly "lets you know when your privacy could be at risk so you can take action to improve it," while at the same time offering access to the Android ecosystem. The Priv has a sliding QWERTY keyboard (a rarity these days), in addition to a 5.4-inch dual-curve Quad HD (1440 x 2560 pixel) display. Other features include LTE connectivity, a six-core Snapdragon 808 processor, 3 GB of RAM, 32 GB of expandable internal memory, and a 3410 mAh battery. An 18 MP rear camera (with OIS and 4K video recording) and a 2 MP front-facing camera complete the specs list.+ View Specs
7.2BlackBerry Priv
Dell Streak 7Compare6.5 reviewDell Streak 7 features a compact (for a tablet) 7-inch Gorilla Glass touchscreen and has Nvidia's Tegra 2 chipset. Unfortunately, this device runs the good old Android 2.2 Froyo treatment. The Dell Streak 7 will run on T-Mo's HSPA+ network, capable of reaching theoretical peaks of 21 Mbps.+ View Specs
6.5Dell Streak 7
Samsung Galaxy S II AT&TCompare9 reviewThe AT&T Samsung Galaxy S II is the closest to the original global version of the Galaxy S II. Don't be fooled by its razor thin profile as under the hood the AT&T-bound Galaxy S II comes with a 1.2GHz dual-core Samsung Exynos processor. The chip powers Android Gingerbread skinned with the latest TouchWiz UI, all showing off on a 4.3" Super AMOLED Plus screen.+ View Specs
9Samsung Galaxy S II AT&T
Alcatel Idol 4S with WindowsCompareThe Idol 4S packs a large 5.5-inch AMOLED display that supports full HD (1080p) resolution and features 2.5D glass finish on the front and back. On the inside, Alcatel's new Windows 10 handset features a 2.15GHz quad-core Qualcomm Snapdragon 820 processor, coupled with 4GB of RAM and 64GB of storage, expandable via microSD card. Another major features included is the 21-megapixel rear-facing camera that offers PDAF (phase detection autofocus) and dual-tone flash. There's also a secondary 8-megapixel camera in the front for selfie lovers.+ View Specs
Alcatel Idol 4S with Windows
Micromax Unite 2Comparethe Micromax Unite 2 is a mid-range phone with Android 4.4.2 out of the box. It offers a 4.7" display in conjunction with 5MP rear camera, a front camera, 1.3 GHz quad core MediaTek chip, 1GB RAM, 4 GB ROM, and microSD card slot.+ View Specs
Micromax Unite 2
LG Prada 3.0Compare8 reviewThe LG Prada 3.0 is the third device to come out of the collaboration between LG and Prada, and it aims to bring Android with a designer zest to the masses. The Prada 3.0 features a 4.3-inch very bright, 800 nit WVGA display. Under the hood, there's a 1GHz dual-core chip, dual-channel RAM memory, while on the back the handset features an 8-megapixel camera. All of this comes in a very thin, 0.33-inch thick body. Software-wise the phone runs on a modified version of Android Gingerbread with simplistic icons aiming to convey the feel of the Prada brand.+ View Specs
8LG Prada 3.0
Samsung Galaxy Tab 7.7ComparepreviewThe Samsung Galaxy Tab 7.7 is the first tablet to feature a 7.7-inch Super AMOLED display. Under the hood, there is a 1.4GHz processor, making the TouchWiz skinned Android Honeycomb 3.2 tick. The tablet sports a 3-megapixel camera on the back and a 2-megapixel front shooter and has a 5100mAh battery, which delivers up to 10 hours of non-stop video playback.+ View Specs
Samsung Galaxy Tab 7.7
Huawei Ascend P1Compare7 reviewThe Huawei Ascend P1 is the thicker brother of Huawei Ascend P1 worlds slimmest smartphone. The P1 has some descent hardware including a 1.5GHz dual-core processor, 1GB of RAM, 8-megapixel camera with 1080p video capture. It is running Android 4.0 and sports a 4.3-inch Super AMOLED screen with 540x960 pixels resolution and Corning Gorilla Glass protection.+ View Specs
7Huawei Ascend P1
Alcatel OneTouch POP 7Compare4.5 reviewThe Alcatel OneTouch POP 7 is a 4.2-running tablet with 7'' display. Its modest specs include 1.3 GHz dual core MediaTek CPU, 1 GB RAM, 4 GB ROM, microSD slot for up to 32 GB additional memory, and 2 cameras - a 2 MP rear one, and 0.3 MP on the front.+ View Specs
4.5Alcatel OneTouch POP 7
BLU Dash 5.5CompareThe BLU Dash 5.5 is a dual-SIM smartphone. On the software side it offers Android 4.2 out of the box. Hardware includes a large 5.5" display with the low res of 480 x 854 px, 1.3 GHz quad core CPU coupled with 512 MB of RAM, 4 GB built-in storage, up to 32 GB extra space expandable via the microSD slot, 5 MP camera on the back and VGA cam for video chat.+ View Specs
BLU Dash 5.5
HTC One X AT&TCompare8.5 reviewHTC One X for AT&T will be flaunting a mighty 4.7-inch 720p HD display with Gorilla Glass, which will be further enhanced thanks to its wide-viewing angles and its ability to connect it to a TV wire-free with the aid of an optional wireless HDMI adapter. Running the show from behind the scenes, its next-generation 1.5GHz Qualcomm Snapdragon S4 dual-core processor (no quad-core folks) will be doing its best to keep things rolling along. Not surprisingly, it'll be flying through the air with its 4G LTE connectivity as well, but for those concerned about battery consumption, it's worth mentioning that it'll be carrying along an 1,800 mAh battery+ View Specs
8.5HTC One X AT&T
LG Optimus G ProCompare8.5 reviewThe LG Optimus G Pro is a high-end Android smartphone offering one of the largest screens to ever grace a handset's front. Its 5.5-inch IPS-LCD display has a resolution of 1080 by 1920 pixels, which translates to excellent pixel density and impressive level of image detail. But at the same time, LG has made the phone as narrow as possible by minimizing the width of the bezel surrounding its screen. Under the hood of the LG Optimus G Pro we see a powerful quad-core Snapdragon 600 SoC running at 1.7GHz alongside 2GB of RAM for seamless multitasking - specs that place it pretty high in the hierarchy of current Android smartphones. The main camera offers 13MP of resolution while the 2MP front-facing camera can take 1080p videos. Further specs include a massive 3140mAh battery, 32GB of internal storage, and a microSD card slot.+ View Specs
8.5LG Optimus G Pro
HTC One SCompare8 reviewHTC One S is a more compact in overall footprint because if its 4.3" qHD Super AMOLED display. Yeah, it might not have the size advantage like AT&T's HTC One X, but regardless of that, we're certain that its Super AMOLED panel will have no problems catching the attention of curious eyes. Other features include a dual-core 1.5GHz Qualcomm Snapdragon S4 processor and HSPA+42 connectivity to really show off its sense for speediness.+ View Specs
8HTC One S
Motorola DROID RAZR MAXX HDCompare8.7 reviewJust like last year, Motorola is making a souped-up version of its RAZR HD, the RAZR MAXX HD. This year it has the HD after its name, hinting that Moto is finally joining the high-res screen party, but will upgrade where it matters again - the battery. The Motorola DROID RAZR MAXX HD will sport the same 4.7" Super AMOLED HD screen as its non-Maxx version (what, Samsung is lending those to others now?), and dual-core Snapdragon S4, but will sport a huge 3, 300mAh battery, just like last year. This will allow it the impressive 13 hours of video playback, 21 hours of talk time, 10 hours of streaming video and 27 hours of streaming music over Verizon's LTE network.+ View Specs
8.7Motorola DROID RAZR MAXX HD
Samsung Focus SCompare8 reviewThe Samsung Focus S strips much of the bulk of the original Focus as it comes with a thin 0.34-inch (8.55mm) body. Under the hood, a 1.4GHz processor runs the Mango goodness. An 8-megapixel camera on the back will add appeal to the Focus S, while up front it comes with a 1.3-megapixel snapper for video conferencing.+ View Specs
8Samsung Focus S
Nokia Lumia 730Compare7.5 reviewThe Windows Phone 8.1-running Dual SIM Nokia Lumia 730 comes disguised as a 'selfie phone', one with a powerful, 5-megapixel front shooter with a wide-angle lens for better looking selfies. Under the hood, the Lumia 730 features a Snapdragon 400 system chip running at up to 1.2GHz, 1GB of RAM and 8GB of internal storage. Unlike the otherwise very similar Lumia 735, the 730 does not support 4G LTE connectivity.+ View Specs
7.5Nokia Lumia 730
Google Nexus 6Compare9 reviewThe Nexus 6 is powered by the Snapdragon 805 system chip, the jewel in Qualcomm's 32-bit crown. This is the last iteration of Qualcomm's Krait CPU core architecture, with four cores running at up to 2.65GHz, along with 3GB of RAM, and Adreno 420 graphics. The devices sports a 5.96" AMOLED screen with 1440x2560 pixels resolution, a 13-megapixel shooter capable of capturing 4K videos, a secondary 2-megapixel unit can be found on the front alongside the two front facing speakers.+ View Specs
9Google Nexus 6
Samsung Galaxy AlphaCompare8.8 reviewApart from the metal frame, the Samsung Galaxy Alpha looks a lot like the Galaxy S5 in terms of design with similarly position buttons and overall styling. Hardware-wise the phone features a 4.7-inch 720p display, Exynos 5 Octa SOC with four cores running at 1.8GHz and four more at 1.3GHz, and 2GB of RAM. The build-in storage is 32GB and can't be expanded via MicroSD. There is 12 megapixels camera on the back (capable of 4K video recording), as well as 2.1 front shooter. The Galaxy Alpha is running Android 4.4.4 KitKat with TouchWiz.+ View Specs
8.8Samsung Galaxy Alpha
Xiaomi Mi-3CompareThe Xiaomi MI-3 is a very slim 8.1mm handset that features a 5-inch 1080p display and the latest Nvidia Tegra 4 chip with amazing graphics capabilities and 2GB of RAM. What's most impressive, though, is its price. The Xiaomi Mi-3 price is set at 1999 yuan ($327) off contract for the most basic 16GB model.+ View Specs
Xiaomi Mi-3
Motorola DROID RAZR HDCompare8.5 reviewDroid RAZR HD is Motorola's flagship with a huge 4.7-inch 720p Super AMOLED screen with no physical buttons, and the Qualcomm Snapdragon S4 chip with the processor clocked at 1.5GHz. The Motorola Droid RAZR HD runs on Android 4.0.4 Ice Cream Sandwich, but Motorola has promised it'd pay you back $100 if it doesn't manage to update the phone to Jelly Bean by the end of the year. The Droid RAZR HD will of course run on Verizon's blazing-fast 4G LTE network and come with Chrome pre-loaded. The handset will also will feature a pretty capable 2,530mAh battery, a capacity surpassing the Droid RAZR by 40%.+ View Specs
8.5Motorola DROID RAZR HD
Samsung Galaxy NotePRO 12.2Compare8 reviewSamsung Galaxy NotePRO 12.2 came as the largest member of the S Pen-wielding family, equipped with powerful processors, 3 GB of RAM and a minimum of 32 GB storage. It takes full advantage of the big screen diagonal by offering Multi Window mode with up to four split-screens, as well as up to $700 worth of preinstalled media consumption and productivity apps and services.+ View Specs
8Samsung Galaxy NotePRO 12.2
Motorola Moto ECompare9 reviewThe Moto E continues on the design legacy of the Moto X and Moto G, with a similar slightly chubby, curvy form with a dimple on the back. The handset comes with a 4.3-inch display with a resolution of 540 x 960 pixels (qHD). This might sound low on paper, but on this small screen, it works out to the very sharp pixel density of 256ppi. Best of all, the Moto E runs on the latest Android 4.4 KitKat. The little new Moto features a Snapdragon 200 system chip with 1.2GHz dual-core Cortex A7-based processor and an Adreno 302 GPU. There's 1GB of RAM, and a scarce 4GB of internal storage (only 2.2GB available to end users!) that you can, luckily, expand via microSD cards. It's also got a 5-megapixel camera (no flash in sight) capable of recording videos with 480 x 854-pixel resolution at 30 frames per second.+ View Specs
9Motorola Moto E
Samsung Focus FlashCompare7.5 reviewSamsung Focus Flash is a Windows Phone 7.5 Mango running device with 3.7-inch Super AMOLED screen. It is powered by a 1.4 GHz processor and features a 5-megapixel camera plus front facing one.+ View Specs
7.5Samsung Focus Flash
Huawei Ascend D1 quad XLCompare7.5 reviewHuawei Ascend D quad XL is the more durable brother of the Ascend D quad, coming with the same specs but with a huge 2600mAh battery which the company says will provide two to three days of normal usage.+ View Specs
7.5Huawei Ascend D1 quad XL
Sony Xperia TLCompare8 reviewThis is the LTE capable version of the Sony Xperia T whic is the company's newest flagship the Android ICS-powered device. Specs-wise, the Xperia T is equipped with a large 4.6" HD BRAVIA display, which will obviously take advantage of the Mobile BRAVIA engine that enhances media for your viewing pleasure. This, however, isn't where the interesting features of this display end. Sony has also employed its WhiteMagic technology here in the Xperia T. What it does is allowing you to set the brightness of the display really high, but the extra white pixel comes at the expense of natural color representation, at least in the Xperia P. NFC is thrown into the ring here, too, for sharing media, files and mobile payments.+ View Specs
8Sony Xperia TL
Samsung Galaxy S3 NeoCompareThe Galaxy S3 Neo is presented by Samsung as "the most premium dual SIM smartphone". The phone has a quad-core 1.2GHz processor, 1.5GB of RAM, dual band Wi-Fi and supports microSD card up to 64GB. The S3 Neo runs Android 4.3 Jelly Bean.+ View Specs
Samsung Galaxy S3 Neo
LG G2Compare9.4 reviewThe LG G2 is a high-end Android smartphone - an embodiment of cutting-edge hardware and precision-polished software, sprinkled with a handful of innovative goodies all over. It comes with top-of-the-line specifications, including a 5.2-inch, 1080p display made using IPS LCD technology, a quad-core Snapdragon 800 chip running at 2.3GHz, and 2GB of RAM. In terms of performance, the device should rank among the best handsets to date. Further down the list we have an advanced 13MP camera that stands out with cool features like optical image stabilization and 1080p video capturing at 60 frames per second. A notable multimedia feature is the support for 24-bit, 192kHz audio. The design of the LG G2 is quite unusual for its volume and power buttons are placed on the back. Its thickness of 9 millimeters is acceptable considering that inside the phone you'll find a 3000mAh removable battery. 32GB of on-board storage are present, expandable further through the use of a microSD card (in some markets).+ View Specs
Motorola Moto G (2014)Compare8.5 reviewWhile most of the buzz has been for its brother the new Moto X, there is officially a new Moto G as well. Of course, there isn't exactly all that much that is new about the device, as it shares quite a bit in common with last year's Moto G. The major difference this year is in the design of the device, while the internals are only a modest update overall compared to last year's Moto G. On the outside, the changes can be summed up in two points: the display is now 5-inches rather than 4.5, and there are stereo front speakers. That's about it. On the inside, the cameras have gotten modest updates (8-megapixels in the rear and 2-megapixels in the front compared to 5MP and 1.3MP), and there is now a microSD card slot. Otherwise, the device has the same Snapdragon 400, 1GB of RAM, swappable shells, and software offerings.+ View Specs
8.5Motorola Moto G (2014)
Samsung GALAXY Note IICompare9 reviewSamsung Galaxy Note II sports a slightly bigger, 5.5-inch display, a quad-core processor that gets rid of the slight lag in the original Note, and best of all Android 4.1 Jelly Bean right out of the box. The Galaxy Note II is armed with a brighter and larger 5.5" HD Super AMOLED display with resolution of 720 x 1280 pixels. While this means that pixel density will be slightly lower compared to the original Note, in reality, the image quality shouldn't suffer any losses, as this screen used the standard RGB matrix, instead of PenTile, which means more subpixels, and ultimately – clarity. The bezel is slimmer, so despite the increase in screen size overall the device is not bigger. Powered by the same Samsung Exynos 4412 quad-core processor that's also found in the Galaxy S III, but clocked up, to the whopping 1.6GHz, the Note II will have no trouble running any application you can think of. The G Note II features an 8-megapixel back-side illuminated (BSI) rear camera and a 1.9-megapixel BSI front shooter. The Samsung Galaxy Note II will ship in three versions - a 16GB, 32GB and 64GB ones, with memory expandable via up to 64GB microSD cards making it possible to have as much as 128GB storage. The second-gen Note is coming with a humongous 3,100mAh battery that should get you through the day.+ View Specs
9Samsung GALAXY Note II
Xiaomi Mi 4Compare8.8 reviewThe Xiaomi Mi 4 comes with a 5-inch 1080p, fully laminated display and top notch hardware: it runs on the quad-core Qualcomm Snapdragon 801 system chip clocked at up to 2.5GHz, and comes with a plentiful 3GB of RAM. The battery is a sizable 3080 mAh pack that can last around a day and a half according to Xiaomi, more than most other 5-inch flagship phones. The Mi 4 also supports quick charging, so you can juice it up to 60% in less than an hour. In terms of cameras, the Mi 4 boasts a 13-megapixel rear one and a high-res, 8-megapixel shooter with a Sony sensor up front. The Mi 4 comes in two versions: one with 16GB of internal storage, and another one that makes a jump directly to 64GB, skipping a 32GB model. The storage is also of the fastest eMMC 5.0 kind.+ View Specs
8.8Xiaomi Mi 4
Sony Xperia LCompare6.5 reviewSony Xperia L is a stylish mid-range device that stands out primarily with photographic skills. There's an 8MP camera on its back with an Exmor RS sensor that enables cool features like HDR mode while shooting photos or video, just like on the Xperia Z flagship. In addition, you get a dedicated shutter key that can snap a photo in under a second straight from the lock screen. Other than that, the Sony Xperia L is your typical mid-range device. It is powered by a dual-core Snapdragon S4 Plus SoC - the Qualcomm MSM8230 running at 1GHz. The 4.3-inch screen has a resolution of 854 by 480 pixels so it isn't quite HD, although it should meet the needs of the average consumer. You can have the smartphone in any color, as long as it is black, white, or red. The exact capacity of the Xperia L battery has not been disclosed, but it should be capable of delivering up to 8 hours and 30 minutes of continuous talk time, or 7 hours and 36 minutes of video playback. Android 4.1 Jelly Bean comes out of the box, sprinkled with a number of interface tweaks on top.+ View Specs
6.5Sony Xperia L
Sony Xperia M2Compare5 reviewThe Sony Xperia M2 has grown considerably, and its display now measures in at 4.8-inches. In comparison, the amount of pixels went through only a minor update - a 540x960 qHD resolution. The processor, now a respectable 1.2GHz quad-core Snapdragon 400, has also seen an upgrade, and allows the Xperia M2 to hook up to a 4G LTE network. While on the topic of connectivity, its worth pointing out that the M2 will also come in a dual SIM version. The rest of the hardware highlights include an 8-megapixel camera, with Sony's proven Exmor RS sensor, 1GB of RAM and 8GB of internal storage, and a fairly large, 2300mAh battery. The M2 will come in the three signature Xperia colors: black, white and purple, and will see a global launch starting April 2014.+ View Specs
5Sony Xperia M2
Nokia Lumia 630Compare7.5 reviewThe Nokia Lumia 630 sports a 4.5-inch FWVGA display, 1.2 GHz processor, 512MB of RAM and 5-megapixels rear-facing camera without flash. The handset runs Windows Phone 8.1 and has dual SIM variant.+ View Specs
7.5Nokia Lumia 630
Nokia Lumia IconCompare8.5 reviewWith the Nokia Lumia Icon as a Verizon exclusive, our prayers for the Lumia 1520's awesome specs to appear in a more manageable body, have seemingly been answered. The handset is way more compact with its 5" Full HD display, but sports the same excellent 20 MP PureView camera with optical image stabilization, and not two or three, but four HAAC mics for noise cancellation, adding to the fast Snapdragon 800 chipset and 2 GB of RAM, making it one of the best Windows Phones a two-year contract can buy.+ View Specs
8.5Nokia Lumia Icon
Motorola Moto GCompare9 reviewLooking at its specs sheet, we're surprised to see how much bang the Moto G can deliver for its money. First and foremost, our eyes are treated to a 4.5-inch "edge-to-edge" LCD display with a resolution of 720 by 1280 pixels. This gives us a figure of around 329ppi, which nothing short of great given the phone's cost. A layer of Gorilla Glass 3 protects the screen against light scratches. Then there's the processor ticking inside of the Moto G – a 1.2GHz, quad-core Snapdragon 400 silicon, which is no slouch by any means. 1GB of RAM is available on the device.+ View Specs
9Motorola Moto G
Users' favorite 4G phones


text:
Father: Pascal Usher Williams
Mother: Sarah Estella McDowell b: 20 JAN 1880
Marriage 1 Rose Adams
RootsWeb.com, Inc. is NOT responsible for the content of the GEDCOMs uploaded through the WorldConnect Program. If you have a problem with a particular entry, please contact the submitter of said entry. You have full control over your GEDCOM. You can change or remove it at any time.


text:
The 2012 Nobel Peace Prize Forum was comprised of several unique tracks and special events that occurred over a 3 day period. The entire Forum was open to the public and people of all ages were encouraged to attend.
Benjamin Britten's "War Requiem": March 1
"Ethics & Hip Hop" featuring Dessa: March 2


text:
Swing state
Religious right and left in Ohio
Oct 03, 2006 by Carol Steele
A recent article in the New Yorker about the race for governor in Ohio declared that the November election would "test the power of the Christian right." It was not the first article to examine the Republican candidate, Ken Blackwell, and his ties to the religious right. As Ohio's secretary of state, Blackwell led the 2004 campaign against gay marriage in Ohio, helping put "Issue One," as the gay marriage amendment was called, on the same ballot as presidential contenders George W. Bush and John Kerry. Voter turnout surged, and Ohio, that ever-wavering swing state, swung for Bush. (Some say Blackwell's control of the election apparatus also played a part.)
This article is available to subscribers only. Please subscribe for full access—subscriptions begin at $2.95. Already have an online account? Log in now. Already a print subscriber? Create an online account for no additional cost.


text:
At a time when operators of just about every stripe are concerned about rising food costs, any tips to help avoid food waste are welcome. We came across an interesting one on the "Food Waste Focus" blog maintained by Andrews Shakman, CEO of Lean Path. Shakman notes that in many cold and central production prep rooms, product is created and dated with expiration dates that don't specify a time of day. "The prep workers know whether the expiration is supposed to occur at the end of the date ...
Register to view this Article
Why Register for FREE?
Registering for Premium Content on Food Management will give you INSTANT access to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It's FREE, easy and quick.


text:
Passiflora Incarnata (Purple), Krishana Kamal - Plant
( 1179 times booked in last 90 days )
The pack contains 5 bulbs each of
- Gladiolus bulbs
- Rajanigandha bulbs
- Zephyranthes bulbs
*Use coupon : FMTFRG
-High Quality 8 inch Plastic Pot with each plant.
-Offer Valid on orders with 3 or more Plants
Common name: wild passion flower
Color: White with purple crown
Bloom time: July to September
Height: 6.00 to 8.00 feet
Difficulty level: easy to grow
Planting & Care
Passiflora incarnata derived the early common name of Maypop from the way it just seems to pop out of the ground in May.
Maypops were eventually renamed as the Passion Flower by missionaries in the early 1500s. The missionaries believed (or professed) that several parts of the plant, including the petals, rays, and sepals, symbolized features of the crucifixion of Christ.
Sunlight: Full sun to part shade
Soil: well-drained soil
Water: Medium
Temprature: 20 °F
Fertilizer: Apply any organic fertilizer
- Passion flowers are considered to be hardy in USDA zones 5-9, but they should be planted in a protected location and mulched heavily if severe cold threatens.
- Only the top growth is killed back by frost, but your Passion Flower will pop back to life in the Spring
Special Feature:
May be used on trellises, arbors, walls or fences. The unique flower and edible fruit make this vine an extremely interesting plant for the garden.
Medicinal use:
- the plant been used as a herbal medicine to treat nervous anxiety and insomnia
Ornamental use:
- The plant is used for ornamental purpose
No serious insect or disease problems.
http://www.thegardenhelper.com/passion.html http://www.missouribotanicalgarden.org/PlantFinder/PlantFinderDetails.aspx?kempercode=q280
You may also need below items with plants
Recommended Planters : Rotomolded Planters :
Add a splash of beauty to balconies, patios, walls, fences & window sills with durable,light weight, Rotomolded planters.
View | Buy Rotomolded Planters | Browse Planters by Size | Buy Colorful Planters >>
Buy ready to use nutrient rich soil:
Buy nutrient rich soil | Buy Fertilizers >>
In general use a soil-based compost placed over a generous layer of drainage material such as earthenware crocks, pebbles or gravel. Water and feed regularly, especially while plants are bearing flowers and fruit, when a high-potash fertilizer is recommended.
Buy Decorative Pebbles :
Decorate planters or garden landscapes with these decorative pebbles :
View Details | Buy Decorative Pebbles >>
Using pebbles in a garden brings different colours and textures to the garden. Pebbles can also fill up otherwise empty space in the garden, leaving a visual that might be considered more interesting and aesthetic than simple dirt, soil or mulch.


text:
If you have a friend or relative that is expecting a child, the baby shower is going to be a very important occasion in their lives. If you are invited to the shower, make sure that you take the time that is necessary to choose a gift that has plenty of meaning. Of course, there are likely to be some suggestions that are given by the parents as to what you can get for the child from specific stores. Even though that is the case, however, there is always going to be some room to purchase other items that may be needed regularly, such as baby bibs and tubbies. You may also want to consider purchasing something that is unique, such as trumpette socks for the child as well (Sources: Trumpette Socks by Burps Bibs and Beyond).
Another way for you to show that you really care about the parents as well as the baby that is due to arrive is to get something that is personal. For example, you may want to consider having some items monogrammed or perhaps putting a special saying on a bib or other items that will remind the parent of you when it is used. You may also want to consider purchasing something that they did not think about it in the original list of items that they needed. For example, when purchasing blankets for baby clothing, try to get something that is organic. The fact that it is organic helps to keep many of the harmful chemicals that may be associated with those items away from the baby's sensitive skin. It is something that the new parents are certain to appreciate.


text:
Marketing Via Rings
Marketing Via Articles
Marketing Via Yellow Pages
Contact Us
Privacy & Disclaimer
Blog Baltimore Is Migrating See Note Below:
+ ADD YOUR SITE (61 members)
Blog Baltimore Is Migrating See Note Below:
Click Member link to see site in tv
Blog Baltimore Is Migrating See Note Below:
+ ADD YOUR SITE (61 members)
NOTE: Baltimore Community has been abandoned by the original owner on the CommunitySurf system and will be migrated to the ZZ OpenCommunity on Feb 1st 2009. All members have received migration information and notification via eMail. You can migrate now by registecommunity your site at http://www.communitysurf.com/community/zzopencommunity/
Meerkat's Den
Blogging about my interests: country music, sacred harp & shape note singing, various TV shows, random Baltimore sightings, random encounters that are funny, stuff that happens to me...
Maryland Sports Fans
Maryland Sports that include team news, player news, and opinions on the Redskins, Ravens, Orioles, and Terps
Live from Bawlmer
The random thoughts and activities of Charissa Costa, an Ohio native transplant, living in Baltimore, Maryland. Home of Maryland crabs, the Orioles, the Honfest, Domino Sugar, Natty Boh, and Bawlmeres ...
timonium 21093
the life and times of a lifelong timoniumite.
are you effin' kidding me?
Chain smoking, drunk, pissed off, but really sissy Mencken wannabes. Also, in Hampden.
Jimbo's Baltimore Year Round Fcommunitye Festival
A weekly weblog calendar and reviews of cutting-edge art, music, theater, movie and culture events in Baltimore
Captain Hops Adventures
Comments, photos and stories about spicing up life with travel, food, music, assorted merriment, and oh yes... beer.
Anne...straight from the hip
No BS. Just life as I see it, straight from the hip
A.D.D. Central
A place where news, current events, politics, comedy, and my brain drivel all combine to create a beautifully brown stream of consciousness. So I've got that going for me...which is nice.
The Power of Cheese
A procrastinator's view of blogdom.
chaos theory
The Unlikely RN
The erratically updated life of a never-thought-she'd-go-to-nursing-school nursing student keeping it real in Charm City.
Cranky Mommy
A 30-Something, semi-neurotic mother to a preschooler rants, whines and complains about everything.
Linda Linda
pointless musings
Todd Blog
Site dedicated to my interest
Vegan Momma
I am 34 years old. I have been vegetarian for over 12 years. I have been Vegan for 6 months. My food intake is mainly raw fruits/vegetables. My daughter loves raw foods. She eats a fair amount of cooked ...
Beyond The Rim
The meandecommunitys of a heart and mind searching for faith and truth in a lying world.
Wahzoo News
The news as we see it.
PsychoPhil - Drink More Beer
Random observations on love, life, and football.
A Doggy's Life
Short, shallow essays pretending to be deep, moving, thought provoking, and applicable to all of mankind, when, in reality, it's nothing more than the mere meditations of a dog.
I live in a part of Southeast Baltimore still not called Canton. I write about what happens to me and give intimate details about my neighbors.
The place to be.
Grace Notes
Theologian and writer Sarah Dylan Breuer offers eclectic observations on pop culture, politics, religion, dreams, ending world poverty, and her quest for the perfect margarita. Oh, and there's Friday catblogging ...
Yirga What, Yirga Who
Random rants about music, sports, movies, TV, and of course, myself.
Privacy and Disclarmer
Related Articles
©2003-2009 www.RingSurf.com
All rights reserved


text:
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.
Katlama, Christinea,b; Valantin, Marc Aa,b; Algarte-Genin, Michelea; Duvivier, Claudinec; Lambert-Niclot, Sidoniea,d; Girard, Pierre Me; Molina, Jean Mf; Hoen, Brunog; Pakianather, Sophiea; Peytavin, Gillesh; Marcelin, Anne Ga,d; Flandre, Philippea,d
aINSERM UMR-S 943 and University Pierre and Marie Curie (UPMC) Paris VI, France
bDepartment of Infectious Diseases, Assistance Publique Hôpitaux de Paris (AP-HP) Pitié-Salpêtrière Hospital and UPMC Paris VI, France
cDepartment of Infectious Diseases, AP-HP, Necker Hospital, France
dDepartment of Virology, AP-HP, Pitié-Salpêtrière Hospital, France
eDepartment of Infectious Diseases, AP-HP, Saint Antoine Hospital, France
fDepartment of Infectious Diseases, AP-HP, Saint Louis Hospital, France
gDepartment of Infectious Diseases, Saint-Jacques Hospital, France
hLaboratory of Toxicology and Pharmacokinetic, AP-HP, Bichat-Claude Bernard Hospital, Paris, France.
Received 7 June, 2010
Revised 5 July, 2010
Accepted 5 July, 2010
Correspondence to Professor Christine Katlama, MD, Hôpital Pitié-Salpêtrière, Paris, France. Tel: +33 1 42 16 01 42; fax: +33 1 42 16 01 26; e-mail: email@example.com
Background: Darunavir/ritonavir (darunavir/r) maintenance strategy, in patients with suppressed HIV RNA viremia, is a potential long-term strategy to avoid nucleoside analogue toxicities and to reduce costs.
Methods: MONOtherapy Inhibitor protease is a prospective, open-label, noninferiority, 96-week safety and efficacy trial in virologically suppressed patients on triple therapy who were randomized to a darunavir/r triple drug regimen or darunavir/r monotherapy. The primary endpoint was the proportion of patients with HIV RNA less than 400 copies/ml at week 48; treatment failure was defined as two consecutive HIV RNA more than 400 copies/ml (time to loss of virologic response) or any change in treatment. The trial had 80% power to show noninferiority for the monotherapy arm (δ=−10%, 90% confidence interval).
Results: A total of 242 patients were screened, 225 of whom were randomized. In the per protocol efficacy analysis, treatment success was 99% on darunavir/r triple drug versus 94% on darunavir/r monotherapy (δ = −4.9%, 90% confidence interval, from −9.1 to −0.8). Similar results were found in intent-to-treat population (92 versus 87.5%, δ = −4.5%, 90% confidence interval from −11.2 to 2.1). Three patients experienced virologic failure on darunavir/monotherapy and none on darunavir/r triple drug. No resistance to protease inhibitor emerged in patients with plasma viral load above 50 copies/ml. The two groups did not differ in the number of serious adverse events.
Conclusion: Darunavir/r monotherapy exhibited efficacy rate over 85% with concordant results in the magnitude of difference with darunavir/r triple drug regimen in both intent-to-treat and per protocol analyses, but discordant conclusions with respect to the noninferiority margin. Patients failing on darunavir/r monotherapy had no emergence of new darunavir resistance mutations preserving future treatment options.
The standard and commonly accepted regimens for the initial treatment of HIV-1 infection involve the use of three drugs from two different classes: two nucleoside reverse transcriptase inhibitors (NRTIs) with either one boosted protease inhibitor or one nonnucleoside reverse transcriptase inhibitor (NNRTI) [1]. Although the regular use of combined antiretroviral therapy has substantially reduced AIDS-related morbidity and mortality, the inability to eradicate HIV with such a regimen requires their prolonged use for a lifetime, making long-term toxicity and cost critical issues in the management of HIV-infected patients [2]. In order to treat the largest number of patients worldwide, a continued search for alternative, effective, safe and affordable long-term therapy is necessary.
The use of NRTI is associated with several adverse effects, including mitochondrial toxicity, lipoatrophy and renal impairment [3–6]. Attempt to limit drug exposure as a strategy has been unsuccessful investigated by structured treatment interruptions [7]. Studies investigating monotherapy such as lopinavir/ritonavir or atazanavir/ritonavir have provided some promising results [8–11]. Monotherapy with a boosted protease inhibitor as a maintenance strategy is attractive because it spares other classes of drugs and reduces toxicity and cost [12]. Darunavir/ritonavir (darunavir/r) is an appropriate candidate for protease inhibitor monotherapy due to its high genetic barrier [13], high potency in wild-type and resistant HIV strains [14] and good pharmacokinetic profile [15,16]. Trials investigating maintenance or first-line therapy with protease inhibitor monotherapy have demonstrated a slightly higher proportion of patients with intermittent viremia, raising the concern about selecting resistance mutations [17,18]. Recent data have shown that the selection of darunavir-resistant mutations from wild-type strains is slower and more difficult than for other protease inhibitors [13,19,20]. Our objective was to evaluate whether monotherapy with darunavir/r could be noninferior in terms of efficacy in comparison with a standard triple drug therapy comprising two NRTIs and darunavir/r.
MONOtherapy Inhibitor protease (MONOI) is an ongoing, 96-week, multicenter, randomized, open-label trial with a primary endpoint at week 48, performed at 32 Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) sites in France. This study included a first phase in which darunavir 600/100 mg twice daily was introduced for 8 weeks as a component of a triple drug regimen in replacement of the protease inhibitor, NNRTI or third NRTI. Patients whose HIV viral load remained lower than 50 copies/ml 4 weeks after darunavir induction (W-4) and who had no severe adverse event (SAE) or darunavir-related toxicity were randomly assigned 1: 1 to continue the triple drug darunavir-containing regimen (darunavir triple therapy) or to stop the two NRTIs (darunavir monotherapy). Randomization was centralized and stratified by HIV-1 RNA level (<versus ≥100 000 copies/ml) prior to first antiretroviral treatment and whether or not the center participates to the body composition substudy. The protocol was amended in June 2007 to allow patients with missing HIV-1 RNA before treatment initiation to be enrolled and randomized in the strata HIV-1 RNA at least 100 000 copies/ml.
The study population consisted of HIV-1-infected patients at least 18 years of age receiving a triple antiretroviral drug regimen. All patients had plasma HIV-1 RNA less than 400 copies/ml for the past 18 months, based on at least four viral load measurements, and less than 50 copies/ml at screening. Patients had no history of virologic failure while receiving a protease inhibitor-containing regimen, a documented CD4 lymphocytes nadir greater than 50 cells/μl and acceptable laboratory results at screening. Patients with a history of HIV-related neurological disease or with hepatitis B coinfection could not be enrolled.
After screening (W-10), study evaluations were completed before trial entry (W-8 and W-4), at randomization and at weeks 4, 8 and every 8 weeks thereafter for the duration of the study. Virologic assessments were performed at local laboratories, all from the HIV virology and resistance network of ANRS. A genotypic resistance test was performed in all patients with a plasma HIV-1 RNA level more than 400 copies/ml confirmed in a second sample within 2 weeks or with two plasma HIV-1 RNA levels more than 50 copies/ml obtained in two consecutive visits. Sequences of the protease and reverse transcriptase genes were determined in each laboratory using the ANRS consensus technique (http://www.hivfrenchresistance.org). Darunavir resistance mutations (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V) were identified from the International AIDS Society-USA resistance testing panel [21].
Laboratory analyses, including CD4 cell count were measured at screening, at entry and every 8 weeks thereafter. Patients' adherence to study-drug regimen was assessed by standardized self-report questionnaires at entry, weeks 4, 24 and 48 [22]. The adherence questionnaire included a 4-day recall. An adherence rate of 100% was defined as no missed doses declared during the previous 4 days at entry, weeks 4, 24 and 48. Adverse clinical and laboratory events were assessed by site investigators and were scored with the use of the adverse-event grading scale of the ANRS. An independent Data and Safety Monitoring Board (DSMB) reviewed interim efficacy and safety results.
The primary endpoint measure was the proportion of patients with treatment success by week 48. Treatment failure was defined as any of the following events: virologic failure; treatment modification or discontinuation; and withdrawal. Virologic failure was defined as two consecutive measurements of HIV-1 RNA more than 400 copies/ml within 2 weeks. Patients with a single value of HIV-1 RNA more than 400 copies/ml and a missing second HIV-1 RNA measurement were also considered as failures. Treatment modification was defined as any modification of antiretroviral therapy.
Secondary efficacy endpoints included the proportion of patients with HIV-1 RNA level less than 50 copies/ml and less than 400 copies/ml at each study visit, changes in the CD4 cell count and emergence of resistance mutations. For these secondary endpoints, missing data due to missed evaluations were ignored.
The protocol was approved by the ethics committee Comité de protection des personnes (CPP) Paris VI Pitié-Salpêtrière and by the Agence Française de Sécurité Sanitaire des Produits de Santé (23 January 2007). All patients provided written informed consent.
Prespecified criteria stated that darunavir monotherapy would be judged noninferior to darunavir triple therapy if the lower limit of the two-sided 90% confidence interval (CI) of the difference in percentage of patients in therapeutic success (monotherapy – triple therapy) was greater than 10%. On this basis, assuming a 90% success rate in both treatment arms, a total of 110 patients per arm would provide approximately 80% power (one-sided, α = 0.05) to assess the noninferiority of darunavir monotherapy compared with darunavir triple therapy.
All patients who underwent randomization and received at least one day of study treatment were included in the intent-to-treat (ITT) population. The per protocol population included all patients from the ITT population except those who did not fulfill the inclusion criteria or withdrew from the study or discontinued study treatment without virologic failure or SAE. Analysis of the primary efficacy endpoint was performed with both per protocol and ITT populations. A secondary analysis was performed stratified according to the level of viral load before treatment initiation. Except for the primary endpoint, all other CIs are given at 95%. An exploratory analysis compared patients who maintained HIV-1 RNA below 50 copies/ml throughout the study to those experiencing at least one HIV-1 RNA level above 50 copies/ml.
The study was designed and conducted by members of the ANRS, Paris, France (MONOI ANRS 136 trial). Janssen-Cilag provided darunavir for this trial.
A total of 242 patients were enrolled in the first phase from March 2007 to April 2008 (Fig. 1). Sixteen patients discontinued the study during this phase for the following reasons: SAE in three patients; darunavir-related toxicity in three patients; patient's decision in six patients; HIV-1 RNA more than 50 copies/ml at W-4 in three patients and lost-to-follow-up in one patient.
The ITT population included 225 randomized patients who received the study treatment and the per protocol population involved 204 patients (102 patients in each arm). Twenty-one patients were not included in the per protocol population for the following reasons: study withdrawal without virologic failure or SAE in six patients; modification of darunavir or any NRTI or treatment intensification without virologic failure or SAE in 10 patients; and violation of inclusion criteria in five patients.
Baseline characteristics were well balanced between the two treatment groups (Table 1). At screening, 69, 19, 10 and 2% of patients were receiving a triple therapy comprising a protease inhibitor, a NNRTI, three NRTIs and another combination therapy, respectively. Main combinations of NRTIs consisted of tenofovir/emtricitabine (33%), zidovudine/lamivudine (24%) or abacavir/lamivudine (16%).
At week 48, in the per protocol population, the proportion of patients with treatment success was 101 of 102 patients (99%) in the darunavir/r triple therapy arm and 96 of 102 patients (94%) in the darunavir/r monotherapy arm (Table 2). The difference between the two groups was −4.9% (90%CI from −9.1 to −0.8), thereby establishing noninferiority of darunavir/r monotherapy to darunavir/r triple therapy. In the ITT population, the proportion of response to therapy was 92% with darunavir/r triple therapy and 87.5% with darunavir/r monotherapy. The difference between the two groups was of same magnitude (−4.5%), but with a larger 90%CI (−11.2 to 2.1), excluding noninferiority. The stratified analysis, on 153 patients with available pretreatment viral load, showed a larger difference in efficacy for patients randomized in the strata with a high level of HIV RNA (Table 2).
Three patients experienced virologic failure in the darunavir/r monotherapy group. One patient with a plasma viral load at week 8 of 2722 copies/ml admitted to low adherence to therapy with a darunavir trough concentration of 1120 ng/ml. The second patient had a viral load at week 24 of 411 copies/ml with an adequate darunavir trough concentration of 3480 ng/ml. The third patient had discontinued therapy at week 32 with a viral load of 484 569 copies/ml. All three patients re-suppressed HIV-1 RNA after the addition of two NRTIs.
At week 48, the proportions of patients with plasma HIV-1 RNA less than 50 copies/ml and less than 400 copies/ml were 94.5% (95%CI 90–99) and 100%, respectively on darunavir/r triple therapy, and 89% (95%CI 83–95) and 97.3% (95%CI 94–100) on darunavir/r monotherapy (Fig. 2a and b). Over the 48 weeks, 91 (81%) and 82 patients (73%) from the ITT population had consistent plasma HIV-1 RNA measurements less than 50 copies/ml on darunavir/r triple therapy and on darunavir/r monotherapy, respectively (Table 3). Concordant results were found for the per protocol analysis. When analysis was stratified on pretreatment viral load, a much lower difference between the two treatment groups was observed in the strata with a low level of HIV-1 RNA for both ITT and per protocol analyses (Table 3).
At week 48, the median CD4 cell count was 574 cells/μl [interquartile range (IQR) 452–825, median increase 36 cells/μl, IQR −71–100] on darunavir/r triple therapy and 621 cells/μl (IQR 481–778, median increase 6 cells/μl, IQR −53–93) on darunavir/r monotherapy (P = 0.58 by the Wilcoxon rank-sum test).
Overall, 74 (33%) patients reported having missed at least one dose over the four evaluations; there were no significant differences among the randomized groups. In terms of primary endpoint, there was no difference between patients with 100% adherence and those with a lower rate of adherence (P = 0.15). However, adherence and the HIV-1 RNA level at baseline were significant predictors of consistent HIV-1 RNA measurements less than 50 copies/ml. Indeed, 19% of patients with 100% adherence had at least one HIV-1 RNA measurement more than 50 copies/ml compared with 32% in patients with a lower rate of adherence (P = 0.03). All eight patients with an HIV-1 RNA level between 50 and 400 copies/ml at baseline had at least one further HIV-1 RNA level more than 50 copies/ml compared with 20% of the patients with HIV-1 RNA level less than 50 copies/ml at baseline (P < 0.0001). A multivariate model including both adherence and HIV-1 RNA level at baseline could not be estimated due to difficulty in the likelihood estimation. Our data, however, suggest that the two variables were independent predictors of consistent HIV-1 RNA measurements less than 50 copies/ml as there was no association between adherence and HIV-1 RNA level at baseline (from the eight patients with an HIV-1 RNA level between 50 and 400 copies/ml at baseline, four patients had 100% adherence and four patients had a lower rate of adherence).
From the three observed virologic failures, one patient had the V11I mutation at failure, but the mutation was also found retrospectively in a previous sample 7 years prior to study entry. No darunavir resistance-associated mutations were found in the other two patients at failure. No darunavir resistance mutations were also found in the 13 other patients having two consecutive plasma HIV-1 RNA more than 50 copies/ml (11 in the darunavir/r monotherapy group and two in the darunavir/r triple therapy).
Adverse events leading to discontinuation of study drugs occurred in five patients in the triple therapy arm and in four patients in the monotherapy arm (Table 4). There was no difference between arms in grade 3–4 clinical events and laboratory abnormalities. Two patients on darunavir/r monotherapy experienced mild neurological transient symptoms – unusual headaches in a 36-year-old woman and seizures in a 66-year-old man with known untreated epilepsy. Cerebrospinal fluid (CSF) investigation showed no abnormality – neither in cell number nor in protein level – other than a CSF viral load of 330 and 580 copies/ml, respectively, contrasting with a suppressed plasma viremia less than 50 copies/ml. Addition of abacavir and lamivudine to darunavir in the two patients led to improvement in clinical symptoms and decrease in CSF viral load to the lower limit of quantification below 200 copies/ml.
The randomized MONOI study confirmed the high efficacy rate of a darunavir monotherapy strategy in experienced patients with an overall proportion over 85% patients maintaining suppressed viremia at week 48. Results were concordant in the magnitude of difference in efficacy between the two randomized arms in both ITT and per protocol analyses, but conclusions were discordant with respect to the noninferiority margin. Although the difference in efficacy was even lower in the ITT analysis (−4.5%) compared with the per protocol analysis (−4.9%), the former analysis did not demonstrate noninferiority due to a larger CI. Indeed, proportions of treatment success in each arm were lower in the ITT analysis, leading to larger variances, compared with the per protocol analysis. To our knowledge, this is the first time that such discordant conclusions between these two standard analyses occurred in an HIV noninferiority trial. It is admitted that when both analyses lead to the same conclusion, confidence in the trial results is increased [23]. In our study, despite high proportions of patients in treatment success on darunavir/r monotherapy in both ITT and per protocol analyses, we cannot simply conclude to the noninferiority of darunavir/r monotherapy to darunavir/r triple therapy.
Guidance on statistical principles for noninferiority clinical trials indicates that non-ITT analyses might be desirable as a protection from falsely concluding noninferiority from ITT analysis [23]. In general, ITT analysis leads to smaller observed treatment effects than if all patients had fully adhered to both the protocol and the study treatments. Then, in noninferiority trials, ITT analysis will often increase the risk of falsely claiming noninferiority. In our study, although the difference in efficacy was smaller for the ITT analysis compared with the per protocol analysis, the former analysis failed to demonstrate the noninferiority of darunavir/r monotherapy to darunavir/r triple therapy, whereas the per protocol analysis showed noninferiority. Recently, a study with similar treatment groups showed that darunavir/r monotherapy was noninferior to a triple drug regimen including darunavir/r in both ITT and per protocol analyses [24]. One of the main differences between the two studies was the use of a different threshold value to define virologic failure: 50 copies/ml in the MONotherapy in Europe with TMC114 (MONET) trial and 400 copies/ml in the MONOI trial [24]. Recent data suggested that a theshold of 50 copies/ml falsely declared virologic failure for an unacceptably high number of patients who ultimately re-suppress <50 copies/ml without a change in antiretroviral treatment [Poster 580 CROI 2009]. In the AIDS Clinical Trials Group study (ACTG) 5202, virologic failure was defined as a confirmed HIV-1 RNA level of at least 1000 copies/ml at or after 16 weeks and before 24 weeks or at least 200 copies/ml at or after 24 weeks [25]. This may be particularly relevant in the context of strategies using drugs with high genetic barrier to resistance.
Interestingly, the stratified analysis showed that the difference in efficacy between the two treatment groups was larger in patients with a high level of pretherapy HIV-1 RNA. These results indicated that patients, with a known HIV-1 RNA below 100 000 copies/ml before treatment initiation and after achieving a durable period of HIV-1 RNA suppression, might be eligible for darunavir/monotherapy. In addition, the three patients who experienced a virologic failure on darunavir/r monotherapy had no evidence of emergence of new darunavir resistance mutations and re-suppressed after re-introduction of two NRTIs.
A higher proportion of intermittent viremia was seen in the patients randomized to darunavir/r monotherapy (Fig. 2), a feature observed not only in maintenance studies of lopinavir/r monotherapy [8,17], but also in a study on antiretroviral-naive patients [26]. In a large majority of patients, these elevations were transient and subsequent HIV-RNA levels were less than 50 copies/ml without any treatment modification. Prolonged periods of low-level viremia might favor the development of resistance mutations as seen with antiretroviral naive patients on lopinavir/r monotherapy [27]. In our study, no new darunavir resistance mutations were found in the virus of patients experiencing two successive measurements of HIV- 1 RNA more than 50 copies/ml. This is of great importance that preserves future treatment options for patients receiving such a strategy. However, longer follow-up is necessary to consolidate the robustness of the strategy. The cause of these episodes of intermittent viremia is not completely clear, though low adherence has been associated with HIV-1 RNA elevations or virologic failure [28,29]. Adherence to therapy in a context of monotherapy is even more crucial than in triple therapy as suggested in our results in which patients who reported missing doses were more likely to have intermittent viremia.
There are now several randomized studies to suggest that protease inhibitor monotherapy could be a valuable maintenance strategy in virologically suppressed patients. Most of them had involved lopinavir/r and had shown similar efficacy to triple drug therapy [8,17]. As in our study, HIV RNA elevations were mainly transient, in the range of 50–200 copies/ml and did not generally lead to treatment emergent drug resistance.
Because HIV replication has to be optimally controlled, there has been concern that a protease inhibitor monotherapy may not be sufficient in all compartments and reservoirs of HIV. In a study of paired CSF/plasma samples from eight HIV-infected patients, median concentration of darunavir was 34 ng/ml, above the IC50 [15]. In our study, the two patients on darunavir/r monotherapy with discordant CSF plasma HIV RNA had undetectable CSF darunavir concentrations, which might explain the low level HIV replication in the CSF. Furthermore, we recently reported several cases of neurological symptoms and discordant plasma/CSF viral replication in patients receiving standard triple therapy reported as adequate penetrations in CSF [30]. Protease inhibitor monotherapy with darunavir offers an effective alternative strategy for long-term control of HIV infection as considering both ITT and per protocol analyses, 87–94% of patients on darunavir/r monotherapy and 92–99% of patients on darunavir/r triple therapy were on treatment success at week 48. Confidence intervals and noninferiority margin were such that noninferiority could not be demonstrated in both ITT and per protocol analyses. Patients failing darunavir/r monotherapy had no emergence of new darunavir resistance mutations, thus preserving all subsequent therapeutic options, including restarting the previously used NRTIs.
Long-term management of antiretroviral therapy over decades will require different strategies for different patient profiles. We think that protease inhibitor monotherapy, and particularly darunavir monotherapy, has proved itself sufficiently to be progressively introduced in clinical practice. The impact of such strategies on fat distribution and potential other benefits of an NRTI-sparing strategy are under evaluation.
We thank the investigators, study coordinators, site and data managers and the patients for their contributions. We thank Janssen-Cilag for providing darunavir for this trial.
Financial support was received from Agence Nationale de Recherche sur le SIDA et les Hépatites Virales, Paris, France (ANRS-MONOI ANRS 136 trial)).
MONOI ANRS 136 Study group includes the following members: Trial chair: C. Katlama; Trial cochairs: MA. Valantin, C. Duvivier; Trial statistician: P. Flandre; Trial virologist: V. Calvez, AG. Marcelin; Trial pharmacologist: G. Peytavin, AM. Taburet; Scientific Committee: C. Katlama, C. Duvivier, MA. Valantin, V. Calvez, AG. Marcelin, G. Peytavin, S. Kolta, P. Flandre, D. Costagliola, M. Genin, M-J. Commoy, AM. Taburet, M. L'Henaff, A. Cheret; Data Safety and Monitoring Board: F. Raffi, R. Garaffo, D. Descamps, G. Chêne.
Participating centers and investigators (all in France) are as follows:
Hôpital Belfort (Belfort): JP. Faller, P. Eglinger. Hôpital Avicenne (Bobigny): M. Bentata, F. Rouges, F. Touam, A. Boudribila. Hôpital St-Jacques (Besançon): B. Hoen, A. Foltzer. Hôpital Saint Louis (Paris) Medecine Interne: AC. Lascoux-Combes. Hôpital Necker (Paris): C. Duvivier, JP. Viard, O. Lortholary, S. Boucly, A. Maignan. Hôpital Bicêtre (Le Kremlin Bicêtre): J. Ghosn, A. Brunet, M. Môle. Hôpital Raymond Poincaré (Garches): P. De Truchis, H. Berthe. Hôpital Jean Verdier (Bondy): V. Jeantils, S. Tassi. Hôpital Tenon (Paris): L. Slama, E. Chakvetaze, C. Fontaine, L. Iordache. Hôpital A. Béclère (Paris): F. Boue, H. Schoen, D. Bornarel. Hôpital G. Pompidou (Paris): C. Piketty, P. Kousignian. Hôpital Cochin (Paris): D. Salmon, T. Tahi, MP. Pietri. Hôpital Henri-Mondor (Créteil): Y. Levy, C. Dumont. Hôpital Pitié-Salpètrière (Paris) Maladies Infectieuses: C. Katlama, MA. Valantin, H. Ait-Mohand, N. Bentaleb, A. Curjol. Hôpital Pitié-Salpètrière (Paris) Medecine Interne: A. Simon, M. Iguerstira, H. Remidi, M. Bonmarchand, N. Edeb, G. Breton. Hôpital St-Antoine (Paris): PM. Girard, Z. Ouazene, B. Lefebvre, C. Lupin. Hôpital Saint Louis (Paris) Maladies Infectieuses: JM. Molina, D. Ponscarme. Hôpital Zobda-Quitman (Fort De France) A. Cabie, S. Pierre-François, V. Beaujolais. Hôpital St-Andre (Bordeaux): P. Morlat, I. Louis, J. Delaune. Hôtel Dieu (Lyon): C. Trepo, L. Cotte, K. Koffi, B. Lebouche, C. Brochier. Hôpital Ste-Marguerite (Marseille): I. Poizot-Martin, A. Menard, O. Faucher, C. Debreux. Hôpital Bichat (Paris): P. Yeni, N. El-Alami, B. Phung, G. Fraqueiro. Hôpital Gui De Chauliac (Montpellier): J. Reynes, JM. Jacquet, C. Tramoni. Hôpital Archet (Nice): P. Dellamonica, S. Ferrando, A. Leplatois. CHU (Rennes): C. Michelet, C. Arvieux, M. Ratajczak. Hôpital Civil (Strasbourg): JM. Lang, D. Rey, P. Fischer. Hôpital Bretonneau (Tours): P. Choutet, P. Naud. Hôpital Purpan (Toulouse): L. Cuzin, B. Marchou, P. Massip, M. Chauveau, I. Lepain, M. Baronne, F. Balsarin. Hôpital A.Michallon (Grenoble): P. Leclercq, Blanc, S. Gerberon. Hôpital Gustave Dron (Tourcoing): Y. Yasdanpanah, E. Aissi, F. Ajana, M. Valette, S. Pavel, C. Marien, S. Dubus. CHU Nancy-Brabois (Nancy): T. May, S. Wassoumbou. Hôtel Dieu (Paris): E. Aslangul.
C.K. has received travel grant, fees for conference or consultancy fees from Abbott, Bristol-Myers-Squibb, Gilead, GlaxoSmithKline, Jansen-Cilag and MSD. P-M.G. has received grants and/or fees for conferences from BMS, Gilead, GSK, Tibotec and MSD, in the previous 12 months. J-M.M. has received consulting and travel fees from Tibotec, BMS, GSK, Abbott, Gilead, and Merck. G.P. has received travel grants, consultancy fees, honoraria, or study grants from various pharmaceutical companies, including Abbott, Boehringer-Ingelheim, Bristol-Myers-Squibb, Gilead Sciences, Glaxo-Smith- Kline, Janssen Merck and Roche. A-G.M. has received consulting and travel fees from Tibotec, BMS, GSK, Abbott, Gilead and Merck. P.F. has received consulting fees from Janssen-Tibotec, Bristol-Myers Squibb, GlaxoSmithKline, and Abbott; and has received travel sponsorships from GlaxoSmithKline.
Clinical trial registration NCT00421551.
The present study is presented in part in 5th IAS conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 18–22 July 2009 (abstract WELBB102).
darunavir; HIV suppressed viremia; maintenance therapy; protease inhibitor monotherapy
© 2010 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Your Email:
Colleague's Email:
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at AIDS.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
Folder Name:
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Forgot Password?
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics
Keyword Highlighting
Highlight selected keywords in the article text.
Search for Similar Articles
You may search for similar articles that contain these same keywords or you may
modify the keyword list to augment your search.


text:
Artist series
this wiki
Ad blocker interference detected!
Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers
Wikia is not accessible if you've made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.
- For a list of AR models, see Category:Artist models.
The Ibanez Artist series (AR series) is a series of electric guitars produced by Hoshino Gakki, first introduced in 1974. It was one of the first series of original models by Ibanez, breaking Ibanez' copy tradition of the early seventies and before. It is Ibanez' own version of the Gibson Les Paul model.
Originally, the Artist series did not only contain the now classic "Artist shaped" models, but also other body shapes like the first Iceman models and various semi-hollow models. By 1979, most of these models were issued as separate series, including the similar named Artist Semi-Acoustic series. By then, the four digit numeral model names were also replaced with the now standard AR + model number format.
Due to popularity of the various Superstrat models of the early nineties, production of Artist models halted in 1992. It was ultimately reintroduced in 1998. Since then, it spawned all kinds of variants, including AX series, also in 1998, the ARC, ART and ARX series in 2006 and 2007, and the ARZ series in 2011.


text:
An amazing chapter in Indiana County sports history came to a close last night as the Penns Manor Comets fell to Bishop McCort in the District 6 playoffs, 32-29. Record-breaking quarterback Danny Ferens battled illness and an aggressive McCort defense and was nearly able to pull it out at the end, as he ran for 273 yards and three touchdowns, threw for another score, and almost pulled off a miraculous comeback at the very end of the game.
McCort scored first, with an opening drive capped by a 28-yard touchdown pass to Jordan Spangler from Zaine Tomkowski, who threw for over 200 yards for the Crushers, with two TDs and he also ran for two. The extra point was missed and the Comets answered with a one-play spectacular run, Ferens darting around the left side, leaping into a pile of tacklers and emerging on the other side to outrace the defense 78 yards for a touchdown. Penns Manor then made the extra point to lead it 7-6 and they scored again on their next drive, with Ferens bulling in from a yard out to make it 14-6.
Tomkowski pulled McCort to within two points with a 2-yard run on 4th down, but the two-point conversion failed and at the half, Penns Manor led, 14-12.
McCort scored twice in the third quarter, converting a fumble into points with a 44-yard drive and a Tomkowski 1-yard run to retake the lead, 8-14. Then Spangler got behind the secondary and caught a 67-yard touchdown pass and it was suddenly 25-14 Crushers, and it became evident that neither team was going to have much success stopping the other. Ferens led Penns Manor down the field, using running back Cody Bytner to offset his own runs, and he answered with a 1-yard scoring run followed by a two-point conversion that made it 25-22 McCort.
The Crushers came right back and got a third-down 18-yard pass to Ryan Siwy, and it was 32-22. Ferens led the Comets down the field yet again and scrambled before finding Ryan Gromley open for a 15 yard touchdown pass, but time was running out, and with the Comets down three it looked very bad. But Ferens intercepted a fourth-down pass and returned it to the McCort 48, where he slipped and fell, and when a McCort player speared him as he lay on the field, it looked like Penns Manor could pull some magic out of their Comets helmets. But the penalty was not called. Still, Ferens drove for a third-and-long first down to the 31 yard line and hurried his team to the line of scrimmage. But his long pass for Corey Brown in the end zone was picked off and Bishop McCort was able to barely hold on for the victory.
Penns Manor finishes 9-2 and Ferens and his senior teammates end a remarkable run, one of the best in Indiana County sports history.
EEO Recruitment Source
Copyright © 2016 Renda. All Rights Reserved.
Kathleen Smathers
Copyright © 2016. All rights reserved.


text:
You're probably paying too much for cell phone service. Wirefly compares hundreds of plans to help you save. Enter what you need (minutes, data, texts) into Wirefly's innovative plan comparison tools and see your savings instantly.Sponsored Listing
WWW/HTTP Software
Open Object Rexx
Home of the Open Object Rexx Project. ooRexx is the open source version of IBM's Object REXX Interpreter. It is upwardly compatible with classic REXX and will execute classic REXX programs unchanged. The project is managed by the Rexx Language Assoc.1,006 weekly downloads
midea string api
Midea is a robust c string api set with regex support, handling fixed width 8 to 64 bit character sets at runtime (no recompilation is required). Initialization routines convert multibyte encodings such as utf8.2 weekly downloads
JSPowerLin - Linux with a Java edge
JSPowerLin - Linux with a Java edge, a lightweight platform for developing and deploying J2EE applications and Java Server Pages on a server or servercluster.1 weekly downloads
Mod_Rexx is an Apache loadable module which interfaces to Rexx. All phases of an Apache request can be processed with Mod_Rexx. It supports Open Object Rexx and Regina Rexx.1 weekly downloads
WEBCHECK device status checking over Web
WebCheck is a simple device (computer, router, firewall) health status checking or monitoring over HTTP protocol. Very useful to keep track the status of of a multiple servers or workstation from remote location.1 weekly downloads
Proxy Pal For Networks
PPFN, it is also a tool to be hidden from any server log, these developers know what they have to do. Do you? If you download this ultimate package you will be able to enjoy the web knowing that you would be safe. So be safe, learn to surf right - PPFN
The ZZ Project
ZZ is an open-source WinFS. ZZ relies on the same fundamental idea as WinFS, namely that a graph-oriented data store is more user-friendly than the usual tree model.
hcap is a small, highly configurable, multi-threaded HTTP proxy server. Its main purpose is to limit the bandwidth of HTTP requests and responses to and from the connecting client.


text:
Price Each
Can a Christian man really maintain a pure heart in America's sexually charged culture? Can he truly honor God with his thought life? The answer is a resounding YES! At the Altar of Sexual Idolatry: 20th Anniversary Edition goes right to the heart and proves it. Put an end to the mystery of lust and step into a life of freedom with the proven biblical answers that have helped thousands. Something new for men at every level of the struggle:
View Now
"The reason I am writing this foreword for Steve is that he has based everything in this book on God's Word. It is foundational, inspirational, confrontational—just what you need. This is your book. Put the Bible and this book side by side—reading them—and let the Word do the work. Thank God for a man like Steve Gallagher, who will tell the truth and let the truth make us free. Live Free!"The Late Dr. Edwin Louis Cole, Founder of Christian Men's Network "At the Altar of Sexual Idolatry is one of the best books out there on this topic. I recommend that you get this book." Beverly LaHaye, Concerned Women for America "I do a lot of counseling of men struggling with sexual addiction. Far more than any book I have encountered, Sexual Idolatry cuts right to the heart of the problem. Steve Gallagher has finally given the evangelical world a book that uses the Word of God to deal with this terrible epidemic."Dr. Robert K. Wetmore, Professor of Theology at Toccoa Falls College "Steve Gallagher has nailed the roots of sexual addiction by naming it an idolatry. This kind of spiritual aggression against God has but one cure at its foundation—brokenness, repentance, and walking daily in the power of the Holy Spirit. God's transforming way is revealed in this book."Dr. Tim Clinton, President of American Association of Christian Counselors "Evangelical Christianity is indebted to Steve Gallagher for turning the pain of his past into a path toward purity for those in bondage to sexual idolatry."Richard Dobbins, Executive Director of Emerge Ministries"A powerful guide to finding inner peace despite the dual rampant onslaught of today's sexually charged culture from without, and the utterly selfish sexual cravings from within."Midwest Book Review"The best book for men period."Roy Ingle, Author of The Seeking Disciple"This book is very well written. It gives a great insight into one of the largest, fastest-growing problems in our country today. I feel that every Christian man should read it."Calvary Christian Fellowship
Hot Acid Bath of Truth!
I bought this book almost two years ago and have found it
to be a remarkably well written resource. I use it for discipleship and men's
group meetings and I even got my campus library to order a couple of copies! It is
intense; it never departs from the source of truth (the Bible); and it cannot
be read without serious conviction if you are struggling with porn. If you are
not struggling with porn this book will help you understand the nature of the
addiction, and how to best help those who are trapped in the cycle. There is no
fluff in this book, every page and paragraph is powerful. - Groovemonster
If you are a Christian who is sincerely struggling against your sin but can't get an abiding victory, this is THE book to get you going in the right direction. The focus of the book is on besetting sexual sin and it is the best I have ever seen on this subject, but it has much wisdom to use against all type of besetting sin. This book is not a "fun" read at all, but it is good strong medicine that can change your life if you are serious about changing. – Mark, Kentucky
I read "Every Mans Battle" and "Out of the Shadows." They may help a normal guy with regular temptation, but they did nothing for me. My lack of self-control and obedience to God has destroyed two marriages. Due in great part to Steve's book, I now truly believe that Christ offers freedom and hope. God's grace enables us to abide in Christ. And just as the illustration Steve used to close his book, when we get off track, God's grace tells us to get right back on. – Scott, TexasI have read several books that tell of the problem all men struggle with: sexual idolatry or at least lust. Christians are no different! In my opinion, every Christian man ought to read this book. This book grabs the bull by the horns, and in a Biblical way. You'll be fully satisfied with this book! - W.T., North Carolina Having read almost every book I can find on the subject I can say that this book is the best out there. We have over 30 people using this book in our addictions group at our church, and all agree it is what happens and it is telling the truth unapologetically. The biblical truth present here has kept me from hurting myself with this sin over and over again. Thanks Steve for this book! If you are going to buy any book, buy this one first then let the others be soft/unhelpful towards you. - A. V. I do a lot of counseling of men struggling with sexual addiction. Far more than any book I have encountered, "At the Altar of Sexual Idolatry" cuts right to the heart of the problem. Steve Gallagher has finally given the evangelical world a book that uses the Word of God to deal with this terrible epidemic. I have given to many men, and almost all have found it remarkably helpful in their battle. PLEASE READ AND APPLY THIS BOOK. - Robert, Toccoa Falls College From the day after I got this book until today, I have not been to a bookstore, theatre, park, bath house, etc. HALLALEUJAH!!! There are many (so-called) Christian books full of psycho-babble (not The Word) on this subject. From my experience many are lacking in their biblical perspective/foundation. The writer of this book points to Jesus and The Cross - man's only TRUE hope for freedom. I thank God for this tool that was supernaturally used in my life to help set me free!!! – W. Bryant, Georgia The book is a completely in-your-face exposition of the divisive power of sexual sin and how it is being used by Satan to fell countless men in the Body of Christ. If you want to camp in your sin and not confront your addiction then don't read this book but find another to stroke your ego. But if you are serious about leaving the depravity of sexual addiction behind then grab this book with both hands. It is founded on Biblical truth and uses testimonies to show you that you are not the only person in the world who struggles in this area (as the devil would like you to believe). – J. P., Bristol, UK Written from a contemporary protestant Christian perspective, the information given here is vital to any man (or woman dealing with a man) seeking to understand and ultimately reject the self-destructive life of sex addiction. There's more to it than "just saying no" and he explains this complex process remarkably well. If you're ready to face reality... and the reality of Jesus Christ whom you may only THINK you know... then you can do no better than to read this book cover to cover. He tells the truth ... which is the only thing that can set you free. – Carol, California If you are looking for a quick fix or just want to be free from a controlling habit, you will not find it here. But if you are really tired of living a self-centered life and want to exchange the self-life for the Christ-Life then I suggest you read this book. – Steven, Brooklyn, NY
Price Each


text:
The Style Gallery is a great new way for you to view, love, and share outfit photos. It's meant to showcase
all the expressive, creative, and inspirational personalities of our community!
Love you too!
Your email has been sent!
Share your store of water or juice with a whole of flock of your friends by assembling this adorable water bottle companion by Qualy! From their Bangkok-based studio, Qualy creates preciously practical home accessories that are constructed from and packed in completely recycled materials - the ideal addition to a uniquely modern and darling decor. Just slide in the trio of slim legs, twist on a bottle of your favorite refreshing beverage, and then push or pull the petite crimson bird that's perched on its nozzle, and this bright white accessory will show how generously practical your precious style can be!
Final Sale: This item cannot be returned or exchanged.
Sorry this item isn't available anymore


text:
|15.04.2013 - SABIC to buy assets of SAR 5 bln Sukuk
|Saudi Basic Industries Corporation (SABIC) has announced its intention to purchase the assets of its third Sukuk, amounting to SAR 5 billion. The purchase of the assets is in accordance with the terms and conditions of the Sukuk, which was issued in May 2008. As a result of this, trading of the Sukuk will cease on 15 April 2013 and the amounts due to the Sukuk holders will be deposited to the Sukuk holders accounts on 15 May 2013 from the companys available cash, said a bourse filing. Subsequently the Sukuk will be delisted and cancelled...............................................Full Article: Source